Cargando…

Ceftaroline Fosamil: A Brief Clinical Review

Ceftaroline is a novel cephalosporin with a favorable tolerability profile and broad in vitro activity against many resistant Gram-positive and common Gram-negative organisms. Ceftaroline fosamil is the first cephalosporin to be approved by the United States Food and Drug Administration (FDA) for th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shirley, Debbie-Ann T., Heil, Emily L., Johnson, J. Kristie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108109/ https://www.ncbi.nlm.nih.gov/pubmed/25134474 http://dx.doi.org/10.1007/s40121-013-0010-x

Ejemplares similares

Use of Ceftaroline Fosamil in Osteomyelitis: CAPTURE Study Experience
por: Johnson, Leonard B., et al.
Publicado: (2019)

Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and its Application
por: Yim, Juwon, et al.
Publicado: (2016)

Ceftaroline-fosamil: Acute eosinophilic pneumonia: case report
Publicado: (2021)

Ceftaroline Fosamil for the Treatment of Community-Acquired Pneumonia: from FOCUS to CAPTURE
por: Carreno, Joseph J., et al.
Publicado: (2014)

Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistant Staphylococcus aureus pneumonia
por: Torres, Antoní, et al.
Publicado: (2023)

809 Contemporary Experience with Ceftaroline Fosamil for the Treatment of Community-acquired Bacterial Pneumonia
por: Johnson, Leonard B, et al.
Publicado: (2014)

Ceftaroline fosamil: clinical experience after 23-month prescription in a tertiary hospital
por: Álvarez, Alicia Alonso, et al.
Publicado: (2021)

Efficacy and effectiveness of Ceftaroline Fosamil in patients with pneumonia: a systematic review and meta-analysis
por: Sotgiu, Giovanni, et al.
Publicado: (2018)

Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia in the intensive care unit
por: Maggiore, Christy, et al.
Publicado: (2015)

Ceftaroline fosamil: A novel anti-Methicillin-resistant Staphylococcus aureus cephalosporin
por: Girish, C., et al.
Publicado: (2011)

Ceftaroline Fosamil for Treatment of Pediatric Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia
por: Esposito, Susanna, et al.
Publicado: (2021)

Ceftaroline fosamil doses and breakpoints for Staphylococcus aureus in complicated skin and soft tissue infections
por: Das, Shampa, et al.
Publicado: (2019)

Ceftaroline fosamil and treatment of acute bacterial skin and skin structure infections: CAPTURE study experience
por: Santos, Paul D, et al.
Publicado: (2013)

Ceftaroline Fosamil as an Alternative for a Severe Methicillin-resistant Staphylococcus aureus Infection: A Case Report
por: Jilani, Talha N, et al.
Publicado: (2018)

Correction to: Ceftaroline Fosamil for Treatment of Pediatric Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia
por: Esposito, Susanna, et al.
Publicado: (2021)

A Retrospective Analysis of Probability of Target Attainment in Community-Acquired Pneumonia: Ceftaroline Fosamil Versus Comparators
por: Cristinacce, Andrew, et al.
Publicado: (2019)

Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Pneumonia with Ceftaroline Fosamil in a Patient with Inhalational Thermal Injury
por: Faris, Janie, et al.
Publicado: (2015)

Pharmacokinetic and Pharmacodynamic Target Attainment in Adult and Pediatric Patients Following Administration of Ceftaroline Fosamil as a 5‐Minute Infusion
por: Riccobene, Todd A., et al.
Publicado: (2021)

1567. Pharmacokinetic/Pharmacodynamic Target Attainment in Adult and Pediatric Patients following Administration of Ceftaroline Fosamil as a 5-Minute Infusion
por: Riccobene, Todd, et al.
Publicado: (2019)

679 Ceftaroline Fosamil (CPT-F) for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) in Obese Patients
por: Kaye, Keith, et al.
Publicado: (2014)

Ceftaroline Fosamil for the Empiric Treatment of Hospitalized Adults with cSSTI: An Economic Analysis from the Perspective of the Spanish National Health System
por: Torres, Antoni, et al.
Publicado: (2022)

Ceftaroline Fosamil for the Treatment of Staphylococcus aureus Bacteremia Secondary to Acute Bacterial Skin and Skin Structure Infections or Community-Acquired Bacterial Pneumonia
por: Vazquez, Jose A., et al.
Publicado: (2015)

The use of extrapolation based on modeling and simulation to support high‐dose regimens of ceftaroline fosamil in pediatric patients with complicated skin and soft‐tissue infections
por: Chan, Phylinda L.S., et al.
Publicado: (2021)

Efficacy and Safety of Ceftaroline Fosamil in Hospitalized Patients with Community-Acquired Pneumonia in China: Subset Analysis of an International Phase 3 Randomized Controlled Trial
por: Zhuo, Chao, et al.
Publicado: (2022)

Open-Label Randomized Trial of Early Clinical Outcomes of Ceftaroline Fosamil Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections at Risk of Methicillin-Resistant Staphylococcus aureus
por: Claeys, Kimberly C., et al.
Publicado: (2019)

Summary of the safety and tolerability of two treatment regimens of ceftaroline fosamil: 600 mg every 8 h versus 600 mg every 12 h
por: Cheng, Karen, et al.
Publicado: (2019)

Impact of Underlying Comorbidities on Outcomes of Patients Treated with Ceftaroline Fosamil for Complicated Skin and Soft Tissue Infections: Pooled Results from Three Phase III Randomized Clinical Trials
por: Wilcox, Mark, et al.
Publicado: (2021)

Ceftaroline
por: Soriano, Alex
Publicado: (2021)

Using an Ordinal Approach to Compare Outcomes Between Vancomycin Versus Ceftaroline or Daptomycin in MRSA Bloodstream Infection
por: Barlow, Ashley, et al.
Publicado: (2021)

Baseline Characteristics and Outcomes Among Patients with Complicated Skin and Soft Tissue Infections Admitted to the Intensive Care Unit: Analysis of the Phase 3 COVERS Randomized Trial of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam
por: Sánchez-García, Miguel, et al.
Publicado: (2020)

Ceftaroline for Severe Methicillin-Resistant Staphylococcus aureus Infections: A Systematic Review
por: Cosimi, Reese A., et al.
Publicado: (2017)

Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumonia
por: Maselli, Diego J, et al.
Publicado: (2012)

Ceftaroline in complicated skin and skin-structure infections
por: Hernandez, Paul O, et al.
Publicado: (2012)

A Phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600 mg every 8 h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbidities
por: Dryden, Matthew, et al.
Publicado: (2016)

2309. Ceftaroline for Central Nervous System and Ocular Infections
por: Siegrist, Emily A, et al.
Publicado: (2022)

204. Clinical Outcomes with Ceftaroline Monotherapy versus Daptomycin-Ceftaroline Combination Therapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia
por: Andonie, Gabriela, et al.
Publicado: (2021)

A Case of Ceftaroline-Associated Thrombocytopenia
por: Jagadish, Ashwin, et al.
Publicado: (2023)

Efficacy and safety of ceftaroline: systematic review and meta-analysis
por: Rosanova, Maria T., et al.
Publicado: (2018)

Ceftaroline-Associated Neutropenia: Case Series and Literature Review of Incidence, Risk Factors, and Outcomes
por: Sullivan, Eva L, et al.
Publicado: (2019)

Ceftaroline-related acute eosinophilic pneumonia
por: Min, Zaw, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a09bibcj6vlab066hlca619s7n